Phesgo indication

Author: uryt

August undefined, 2024

WebNov 16, 2024 · PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1)]. WebAug 9, 2024 · Drug Indication. Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a health care provider at home. It is approved for people with early or metastatic HER2-positive breast cancer. General Info.

NDC 50242-260 Phesgo Label Information

WebPhesgo ™ (pertuzumab ... − Phesgo has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. − Refer to the package insert for timing and sequence of dosing with other chemotherapy. WebMar 1, 2024 · PHESGO comes in the following dosage forms: • Loading dose: Sterile solution in a 20 mL vial containing 1200 mg pertuzumab ( 80 mg/mL) and 600 mg trastuzumab (40 mg/mL). • Maintenance dose: Sterile solution in a15 mL vial containing 600 mg pertuzumab (60 mg/mL) and 600 mg trastuzumab (60 mg/mL). Do not use PHESGO if: bright health care pa form

FDA approves combination of pertuzumab, trastuzumab, …

WebNov 16, 2024 · PHESGO is for subcutaneous use only in the thigh. Do not administer intravenously. PHESGO has different dosage and administration instructions than … WebWhat does PHESGO treat? PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:. use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or … WebMar 2, 2024 · Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have … bright floral 80s couch

Genentech: Phesgo® (pertuzumab, trastuzumab, and …

WebINDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: • … WebJul 10, 2024 · Get emergency medical help if you have signs of an allergic reaction: hives, rash; fever, chills, dizziness; nausea, vomiting, diarrhea; chest pain, difficult breathing; swelling of your face,... bright cow malaysiaWebPhesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received … bright flowers clipart

"WebUse of PHESGO for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous pertuzumab and intravenous trastuzumab administered in combination with chemotherapy in adults with HER2-overexpressing early breast cancer (NCT00545688, NCT00976989, NCT02132949, NCT01358877) and … " - Phesgo indication

Phesgo indication

PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) A …

WebJun 29, 2024 · Phesgo may cause serious lung problems. A patient’s doctor may check for signs of lung problems including: Severe shortness of breath Fluid in or around the lungs Weakening of the valve between the heart and the lungs Not enough oxygen in the body Swelling of the lungs Scarring of the lungs Who should not receive Phesgo? WebPhesgo can be administered by a healthcare professional in a treatment centre or at a patient’s home. Phesgo is approved with the same indications as IV Perjeta in many regions worldwide, including EU countries and the US. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Did you know?

WebJul 10, 2024 · anemia; feeling weak or tired; hair loss; rash; or. numbness, tingling, or burning pain in your hands or feet. This is not a complete list of side effects and others … WebMay 2, 2024 · Phesgo has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. Refer to the package insert for timing and sequence of …

WebAug 9, 2024 · Drug Indication. Phesgo is an injectable fixed-dose combination regimen containing pertuzumab, trastuzumab and hyaluronidase that can be administered by a … WebPhesgo is indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer …

WebYour doctor or nurse will check for side effects during your injection and for: 30 minutes after the first injection of Phesgo. 15 minutes after subsequent injection of Phesgo. If you get any serious reaction, your doctor may stop treatment with Phesgo. Low levels of white blood cells and fever (Febrile neutropenia) WebUse of PHESGO for this indication is supported by evidence from adequate and well-controlled studies conducted with intravenous pertuzumab and intravenous trastuzumab …

WebOct 13, 2024 · Phesgo Consumer Information Get emergency medical help if you have signs of an allergic reaction: hives, rash; fever, chills, dizziness; nausea, vomiting, diarrhea; chest pain, difficult breathing; swelling of your face, lips, tongue, or throat. This medicine can cause life-threatening heart or lung problems. Call your doctor at once if you have:

WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … bright health claim dispute formWebIndication Early Breast Cancer PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with ... • PHESGO may exacerbate chemotherapy-induced neutropenia. In randomized controlled clinical trials with intravenous trastuzumab, Grade 3-4 neutropenia and febrile neutropenia were higher in patients ... bright dusk color volvoWebJun 23, 2024 · Phesgo Phesgo Injection, Subcutaneous Solution Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, … bright green snake with yellow stripeWebPHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients. Additional Important Safety … bright health nc medicaidWebOct 13, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of HER2 /neu receptor antagonists and an endoglycosidase indicated for use in … bright health care insurance contact number bright health umWebThe recommended dosage and administration schedule for PHESGO are shown in Table 1. Table 1: Recommended Dosage and Administration Schedule Dose Strength … bright day calendar company